SAINT-GOBAIN STRENGTHENS ITS POSITION IN BIOTECHNOLOGIES

Saint-Gobain has decided to invest around €16m to establish in 2020 a leading-edge industrial facility to manufacture bioprocesses in the Songdo Biocluster in Incheon (South Korea).

The Life Science BU and Samsung BioLogics, the biopharmaceutical unit of the Samsung Group, signed on December 4 a strategic partnership for the supply of single-use systems. This investment enables the BU to enhance its customer focus and its supply chain, to better serve biopharmaceutical industries in Korea.

In this way, by locating its development and manufacturing capabilities in this new plant, Saint-Gobain has become a key contributor to the fast-growing biotechnology market, and will contribute to the economic development and the creation of jobs in this region of Korea.

This new facility will also manufacture products for customers in the automotive, electronics, industrial and habitat sectors.